论文部分内容阅读
目的观察雷替曲塞联合腹部热疗治疗老年结直肠癌的疗效和安全性。方法 60例杭州市肿瘤医院2011年3月至2012年3月收治的符合入组条件的结直肠癌患者,单药雷替曲塞化疗(3 mg/m2,静脉滴注,给药1次),3周重复,联合腹部热疗2次/周,连续8次为1疗程;治疗2个周期后进行有效性和安全性评估。结果患者总体耐受性良好,3例患者因不能耐受化疗不良反应退出化疗,所有患者均完成局部热疗。治疗总有效率为60.0%,疾病控制率为90.0%,1年生存率为65%;主要不良反应为消化道反应、血液学毒性,Ⅲ或Ⅳ级不良反应发生率约10%。结论雷替曲塞联合腹部热疗治疗老年结直肠癌的疗效确切,不良反应较轻,能明显改善患者的生活质量。
Objective To observe the efficacy and safety of raltiprex combined with abdominal hyperthermia in the treatment of elderly patients with colorectal cancer. Methods Sixty patients with colorectal cancer who met the enrollment conditions from March 2011 to March 2012 in Hangzhou Cancer Hospital were treated with single-dose raltitrexed chemotherapy (3 mg/m2, intravenous drip, 1 dose). Repeated for 3 weeks, combined abdominal hyperthermia twice/week, 8 times for 1 course of treatment; efficacy and safety assessment after 2 cycles of treatment. Results The overall tolerability of patients was good. Three patients withdrew chemotherapy because they could not tolerate adverse chemotherapy reactions. All patients completed local hyperthermia. The total effective rate of treatment was 60.0%, the disease control rate was 90.0%, and the 1-year survival rate was 65%. The main adverse reactions were gastrointestinal reactions and hematological toxicity. The incidence of grade III or IV adverse reactions was about 10%. Conclusion The efficacy of raltitrexed combined with abdominal hyperthermia in the treatment of elderly patients with colorectal cancer is definite, and the adverse reactions are lighter and can significantly improve the quality of life of patients.